ArticleDrug delivery and translational research2020
In vitro and in vivo evaluation of cubosomal nanoparticles as an ocular delivery system for fluconazole in treatment of keratomycosis.
Article in Drug delivery and translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 58 citations in OpenAlex.
- Review
- An Insight into Cubosomal Drug Delivery Approaches: An Explicative Review.Pharmaceutical nanotechnology · 2025Review
- Nanoemulsion Carriers for Ocular Fungal Infection: Main Emphasis on Keratomycosis.Pharmaceutical nanotechnology · 2025Review
- Nanomedicine in fungal keratitis: current applications and future prospects.Frontiers in microbiology · 2025Review
- Recent Advances in Ocular Drug Delivery: Insights into Lyotropic Liquid Crystals.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Development of antifungal fibrous ocular insert using freeze-drying technique.Drug delivery and translational research · 2024Article
- Optimization of hyaluronan-enriched cubosomes for bromfenac delivery enhancing corneal permeation: characterization, ex vivo, and in vivo evaluation.Drug delivery · 2023Article
- Article
- Travoprost Liquid Nanocrystals: An Innovative Armamentarium for Effective Glaucoma Therapy.Pharmaceutics · 2023Article
- Sertaconazole-Nitrate-Loaded Leciplex for Treating Keratomycosis: Optimization Using D-Optimal Design and In Vitro, Ex Vivo, and In Vivo Studies.Pharmaceutics · 2022Article
- Combination of Meropenem and Zinc Oxide Nanoparticles; Antimicrobial Synergism, Exaggerated Antibiofilm Activity, and Efficient Therapeutic Strategy against Bacterial Keratitis.Antibiotics (Basel, Switzerland) · 2022Article
- Ameliorative Effect of Dabigatran on CFA-Induced Rheumatoid Arthritis via Modulating Kallikrein-Kinin System in Rats.International journal of molecular sciences · 2022Article
- Advantages of Cubosomal Formulation for Gatifloxacin Delivery in the Treatment of Bacterial Keratitis: In Vitro and In Vivo Approach Using Clinical Isolate of Methicillin-ResistantMaterials (Basel, Switzerland) · 2022Article
- Nanocubosomal basedDrug delivery · 2021Article
- Soil-Associated Bacillus Species: A Reservoir of Bioactive Compounds with Potential Therapeutic Activity against Human Pathogens.Microorganisms · 2021Article
- Lipid-Based Nanocarriers as Topical Drug Delivery Systems for Intraocular Diseases.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the present study was to enhance ocular antifungal activity of fluconazole (FCZ) in treatment of keratomycosis through incorporation into cubosomal nanoparticles. FCZ-loaded cubosomal dispersions were prepared by emulsification method according to 2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.